MGX vs RVTY · rev $25.2M vs P/E 42, rev $1.44B
Metagenomi, Inc. Common Stock (MGX) versus Revvity Inc. (RVTY) — a side-by-side from cached financials, not a winner call.
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ.
Revvity Inc. (RVTY) is a diagnostics & research company listed on US.
Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.
Latest reported RVTY revenue for 2026-07-05 was $1.44B. Net income was $92.5M. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
MGX currently screens at market cap $44.4M. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
Not investment advice. Open the MGX and RVTY stock pages for the full models.
Not investment advice.